Cost-effectiveness of long-acting insulin analogues vs intermediate/long-acting human insulin for type 1 diabetes: A population-based cohort followed over 10 years.

Lee, Tsung-Ying; Kuo, Shihchen; Yang, Chen-Yi; Ou, Huang-Tz

Lee, Tsung-Ying; Kuo, Shihchen; Yang, Chen-Yi; Ou, Huang-Tz.

Afiliação

Lee TY; School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Kuo S; Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Yang CY; School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Ou HT; School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Br J Clin Pharmacol ; 86(5): 852-860, 2020 05.

Article em En | MEDLINE | ID: mdl-31782975

Assuntos

Diabetes Mellitus Tipo 1; Diabetes Mellitus Tipo 2; Insulina de Ação Prolongada; Análise Custo-Benefício; Diabetes Mellitus Tipo 1/tratamento farmacológico; Humanos; Hipoglicemiantes/economia; Hipoglicemiantes/uso terapêutico; Insulina; Insulina Glargina; Insulina de Ação Prolongada/economia; Insulina de Ação Prolongada/uso terapêutico

Palavras-chave

cost-effectiveness analysis; intermediate/long-acting human insulin; long-acting insulin analogues; longitudinal cohort study; type 1 diabetes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Insulina de Ação Prolongada / Diabetes Mellitus Tipo 1 / Diabetes Mellitus Tipo 2 Tipo de estudo: Health_economic_evaluation / Risk_factors_studies Limite: Humans Idioma: En Revista: Br J Clin Pharmacol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Taiwan

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google